Gotistobart reached 18.5 months median survival versus 10.0 months for chemotherapy in 87 previously treated squamous lung cancer patients. Pivotal data pending.
Gotistobart Nearly Doubled Median Survival Versus Chemotherapy in 87 Patient Lung Cancer Trial Stage, Pivotal Data Pending
by | Sep 14, 2026 | Uncategorized | 0 comments
Recent Comments